Overview

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

Status:
RECRUITING
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.
Phase:
PHASE4
Details
Lead Sponsor:
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Treatments:
Liraglutide
Metformin